Dupixent Lymphoma (CTCL) Lawsuits

Updated October 2026

Dupixent (dupilumab), made by Sanofi and Regeneron, is widely prescribed for eczema, asthma and other conditions. New lawsuits allege it can cause or accelerate cutaneous T-cell lymphoma (CTCL), a rare cancer, and that patients were not warned.

The litigation is at an early stage. The manufacturers deny the claims.

Where the Litigation Stands

• Case: MDL No. 3180, U.S. District Court for the District of New Jersey, before Judge Zahid N. Quraishi.
• Formed: June 2026.
• Size: 35 cases as of September 2026, and growing.
• Next steps: the court is setting leadership and an initial schedule.

Who May Qualify

• You used Dupixent
• You were later diagnosed with CTCL, including mycosis fungoides or Sézary syndrome
• Family members may have a claim if a loved one died

CTCL can look like eczema at first, so some patients were diagnosed late. If your “eczema” was later found to be lymphoma, that history matters.

What to Gather

• Prescription records for Dupixent
• Dermatology and oncology records, including biopsy results
• The dates you started and stopped Dupixent

Frequently Asked Questions

Should I stop taking Dupixent?

Talk to your doctor before changing any medication. A lawsuit is not medical advice.

Is it too early to file?

No. Early cases help shape the litigation, and deadlines can run while you wait.